Clinical trials: Dual Diagnosis
Bloody Diarrhea, STEC, Unspecified
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
The investigational medicinal product (IMP), INM004, proposes to neutralize the toxin in the bloodstream to prevent the interaction of the Stx with the specific receptor, by means of a polyclonal antibody to be administered upon…
- Conditions
- Bloody Diarrhea, STEC, Unspecified, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease
- Trial name
- NCT04132375
- Testing
- INM004
- Where
- 7 sites in Argentina
- Volunteers
- 11 people
- Sponsor
- Inmunova S.A.
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
HIV Infections
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment.
- Trial name
- NCT00000912
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 475 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A
Flufenamic Acid for Hospitalised Influenza Infection
It is well recognized that respiratory viruses cause substantial disease burden every year. Among all known respiratory viruses, influenza virus is the greatest cause of disability-adjusted life years lost, excess…
- Trial name
- NCT03238612
- Testing
- FFA, clarithromycin, oseltamivir, Oseltamivir alone
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Parkinson Disease
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
- Trial name
- NCT02970019
- Testing
- K0706
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Diabetes Mellitus Type 2
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients…
- Trial name
- NCT02373865
- Testing
- Sitagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- GWT-TUD GmbH
Type 2 Diabetes
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2 diabetes.
- Trial name
- NCT00263965
- Testing
- Tesaglitazar, Metformin, Dietary and lifestyle modification counseling
- Where
- 3 sites in Finland, Italy and 1 more
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Primary Objective: To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in Chinese patients with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT03760965
- Testing
- sotagliflozin (SAR439954)
- Where
- 29 sites in China
- Volunteers
- 276 people
- Sponsor
- Sanofi
B Cell Leukemia, B Cell Lymphoma
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells.
- Trial name
- NCT03398967
- Testing
- Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Head and Neck Cancer, Taste Dysfunction
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and…
- Trial name
- NCT05273307
- Testing
- Miraculin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Fibromyalgia
A Study For Pregabalin In Patients With Fibromyalgia
The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults.
- Trial name
- NCT01387607
- Testing
- pregabalin
- Where
- 22 sites in China
- Volunteers
- 343 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Rheumatoid Arthritis
Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT03139136
- Testing
- MBS2320
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 121 people
- Sponsor
- Modern Biosciences Ltd
Cough
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The study is split into two parts. Part A will assess the safety and tolerability of the new drug.
- Trial name
- FTIH (NCT01494636)
- Testing
- GSK2339345 (solution), GSK2339345 (nebulised), Lidocaine
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neuromodulation, Upper Limb
Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Upper Limb: a Double-blind Randomized Clinical Trial
This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the upper limb, as well as to determine the difference between two and three sessions per week.
- Conditions
- Neuromodulation, Upper Limb, Musculoskeletal Disorders
- Trial name
- NCT07165392
- Testing
- Neuromodulation, Physical Exercise, Stretching
- Volunteers
- 120 people
- Sponsor
- University of Malaga
Type 2 Diabetes Mellitus, Diabetes
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects.
- Trial name
- NCT02455011
- Testing
- REMD-477
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- REMD Biotherapeutics, Inc.
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Pruritus
Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P
The purpose of this study is to test whether VLY-686 can prevent or reduce the itch and dermatological reaction observed after healthy volunteers are injected with Substance P in comparison with placebo.
- Trial name
- NCT01919944
- Testing
- VLY-686
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
PRIMARY: To examine the safety and potential improvement in immune responses elicited by combining rsgp120/HIV-1MN with the adjuvant QS-21.
- Trial name
- NCT00001044
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)